Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Vascularized Cardiac Tissue Engineering: From Advances in Biofabrication to Translational Applications

Liu Y., Zhang Z., Li H., Prados-Martin L., Li H., Cheng F.

Narrative Review on Cardiovascular Disease, published in Adv Sci (Weinh) (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Adv Sci (Weinh) (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41867079
PMCID
PMC13104096
DOI
10.1002/advs.74917
Citations
1

Abstract (original English)

The in vitro engineering of vascularized cardiac tissues holds transformative potential for disease modeling, drug screening, and regenerative therapy. However, despite rapid advances in stem cell biology, biomaterials, and biofabrication technologies, the reconstruction of functional, perfusable vasculature within engineered myocardial tissues remains a central and unresolved challenge. In this review, we move beyond a descriptive catalog of available techniques and instead present a process-oriented framework for understanding vascularized cardiac tissue engineering. By systematically analyzing how cellular components, biomaterial design, and biofabrication strategies collectively govern vascular formation, perfusion stability, and myocardial function, we examine self-assembly, mold-casting, 3D bioprinting, and microfluidic approaches, to critically evaluate their respective advantages and trade-offs under cardiac-specific physiological constraints. Finally, application prospects of vascularized cardiac tissues in disease modeling and drug testing are discussed, and current limitations and future directions are proposed to accelerate translational impact. By reframing vascularized cardiac tissue engineering as an integrated manufacturing challenge rather than a collection of isolated technologies, this review aims to provide a coherent conceptual guide for advancing functiona

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
MyocardiumHeartAnimalsHumansBiocompatible MaterialsTissue EngineeringTissue ScaffoldsBioprintingTranslational Research, Biomedical

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research